Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis.

Slipicevic A, Øy GF, Rosnes AK, Stakkestad Ø, Emilsen E, Engesæter B, Mælandsmo GM, Flørenes VA.

Cancer Biol Ther. 2013 Feb;14(2):146-54. doi: 10.4161/cbt.22953. Epub 2012 Nov 28.

PMID:
23192275
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy.

Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A, Flørenes VA.

PLoS One. 2012;7(6):e38254. doi: 10.1371/journal.pone.0038254. Epub 2012 Jun 12.

PMID:
22719872
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival.

Hetland TE, Nymoen DA, Emilsen E, Kærn J, Tropé CG, Flørenes VA, Davidson B.

Gynecol Oncol. 2012 Sep;126(3):460-5. doi: 10.1016/j.ygyno.2012.05.029. Epub 2012 May 28.

PMID:
22652154
[PubMed - indexed for MEDLINE]
4.

Synthetic retinoid CD437 induces apoptosis and acts synergistically with TRAIL receptor-2 agonist in malignant melanoma.

Magnussen GI, Ree Rosnes AK, Shahzidi S, Dong HP, Emilsen E, Engesæter B, Flørenes VA.

Biochem Biophys Res Commun. 2012 Apr 13;420(3):516-22. doi: 10.1016/j.bbrc.2012.03.023. Epub 2012 Mar 13.

PMID:
22446330
[PubMed - indexed for MEDLINE]
5.

Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival.

Slipicevic A, Holm R, Emilsen E, Ree Rosnes AK, Welch DR, Mælandsmo GM, Flørenes VA.

BMC Cancer. 2012 Feb 22;12:73. doi: 10.1186/1471-2407-12-73.

PMID:
22356677
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Measurement of apoptosis in cytological specimens by flow cytometry: comparison of Annexin V, caspase cleavage and dUTP incorporation assays.

Dong HP, Holth A, Ruud MG, Emilsen E, Risberg B, Davidson B.

Cytopathology. 2011 Dec;22(6):365-72. doi: 10.1111/j.1365-2303.2010.00811.x. Epub 2010 Nov 3.

PMID:
21054589
[PubMed - indexed for MEDLINE]
7.

Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1.

Hjortland GO, Bjørnland K, Pettersen S, Garman-Vik SS, Emilsen E, Nesland JM, Fodstad O, Engebraaten O.

Clin Exp Metastasis. 2003;20(4):301-9.

PMID:
12856717
[PubMed - indexed for MEDLINE]
8.

Role of the multidrug resistance protein 1 gene in the carcinogenicity of aflatoxin B1: investigations using mrp1-null mice.

Lorico A, Nesland J, Emilsen E, Fodstad O, Rappa G.

Toxicology. 2002 Feb 28;171(2-3):201-5.

PMID:
11836025
[PubMed - indexed for MEDLINE]
9.

Cultured anaplastic cell lines as immunocytochemistry controls: a comparison of ThinPrep-processed smears and conventional air-dried cytospins.

Wiatrowska BA, Berner A, Torlakovic G, Emilsen E, Mykelbost GL, Torlakovic E.

Diagn Cytopathol. 2001 Nov;25(5):303-8.

PMID:
11747220
[PubMed - indexed for MEDLINE]
10.

Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.

Davidson B, Risberg B, Kristensen G, Kvalheim G, Emilsen E, Bjåmer A, Berner A.

Virchows Arch. 1999 Jul;435(1):43-9.

PMID:
10431845
[PubMed - indexed for MEDLINE]
11.

Type 1 protein tyrosine kinases in benign and malignant breast lesions.

Suo Z, Emilsen E, Tveit KM, Nesland JM.

Histopathology. 1998 Dec;33(6):514-21.

PMID:
9870145
[PubMed - indexed for MEDLINE]
12.

A novel grid polymerase chain reaction (G-PCR) approach at ultrastructural level to detect target DNA in cell cultures and tissues.

Kareem BN, Karlsen F, Holm R, Hennig EM, Suo Z, Emilsen E, Hellesylt E, Nesland JM.

J Pathol. 1997 Dec;183(4):486-93.

PMID:
9496267
[PubMed - indexed for MEDLINE]
13.

Invasion potential and N-acetylgalactosamine expression in a human melanoma model.

Rye PD, Fodstad O, Emilsen E, Bryne M.

Int J Cancer. 1998 Feb 9;75(4):609-14.

PMID:
9466664
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk